Naringin sensitizes human prostate cancer cells to paclitaxel therapy.

ABSTRACT:

Background

The aim of the study was to evaluate whether the use of chemotherapy in combination with naringin, a dietary plant polyphenolic flavonoid, could enhance the therapeutic efficacy of paclitaxel treatment in human prostate cancer (PCa) cells.

Materials and methods

DU145, PC3, and LNCaP cells were treated with various concentrations of paclitaxel, naringin, and their combinations. Methylthiazolyldiphenyl-tetrazolium bromide (MTT), image-based cytometer, quantitative reverse transcription PCR (RT-qPCR), Western blot, and transwell assay were used to evaluate cell viability, apoptosis and cell cycle, the mRNA expression, protein expression, and cell migration, respectively.

Results

Naringin treatment inhibited cell survival in a dose- and time-dependent manner by

SUBMITTER: Erdogan S 

PROVIDER: S-EPMC6251953 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature